<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic <z:mp ids='MP_0001845'>inflammation</z:mp> as evidenced by the Glasgow prognostic score (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e>) predicts <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival in various types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to evaluate the significance of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> in patients with both synchronous and metachronous unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (CRLM) </plain></SENT>
<SENT sid="2" pm="."><plain>The subjects were 40 patients who were diagnosed as having unresectable CRLM between March 2000 and August 2010 at Jikei University Hospital </plain></SENT>
<SENT sid="3" pm="."><plain>For the assessment of systemic <z:mp ids='MP_0001845'>inflammatory response</z:mp> using the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e>, the patients were classified into three groups: patients with <z:mpath ids='MPATH_458'>normal</z:mpath> albumin (≥3.5 g/dl) and <z:mpath ids='MPATH_458'>normal</z:mpath> CRP (≤1.0 mg/dl) as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> 0 (n=27), those with low albumin (&lt;3.5 g/dl) or elevated CRP (&gt;1.0 mg/dl) as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> 1 (n=6), and both low albumin (&lt;3.5 g/dl) and elevated CRP (&gt;1.0 mg/dl) as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> 2 (n=7) </plain></SENT>
<SENT sid="4" pm="."><plain>We retrospectively investigated the relationship between patient characteristics including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> and survival using univariate and multivariate analyses </plain></SENT>
<SENT sid="5" pm="."><plain>Results of the univariate analysis revealed that absence of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> resection (p=0.0161), absence of systemic chemotherapy (p=0.0119), serum carcinoembroynic antigen (CEA) of ≥100 ng/ml (p=0.0148), serum carbohydrate antigen (CA)19-9 of ≥100 U/ml (p&lt;0.0001) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> 2 (p=0.0362) were significant predictors of poor survival </plain></SENT>
<SENT sid="6" pm="."><plain>Results of the multivariate analysis revealed that serum CEA of ≥100 ng/ml (p=0.0015), CA19-9 of ≥100 U/ml (p&lt;0.0001) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> 2 (p=0.0042) were independent predictors </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> at diagnosis of unresectable CRLM is an independent prognostic predictor of overall survival </plain></SENT>
</text></document>